NBIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neurocrine Biosciences Inc (NBIX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and strategic acquisition of Soleno Therapeutics provide a solid foundation for growth. While technical indicators are neutral, the long-term potential outweighs short-term fluctuations.
The MACD is slightly positive at 0.0538, indicating mild bullish momentum. RSI is neutral at 47.423, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot point of 129.993, with resistance at 133.229 and support at 126.758.
Acquisition of Soleno Therapeutics for $2.9B, adding immediate accretive revenue and diversifying revenue streams.
Strong financial performance in Q4 2025, with revenue up 28.33% YoY and net income up 49.08% YoY.
Positive analyst sentiment with multiple price target increases, including Citi's target of $242 and Oppenheimer's target of $220.
Seasonal headwinds and fewer selling days in Q1 may impact near-term performance.
A 'light pipeline catalyst year' in 2026, as noted by analysts.
In Q4 2025, revenue increased by 28.33% YoY to $805.5M, net income rose by 49.08% YoY to $153.7M, and EPS grew by 48% YoY to 1.48. Gross margin slightly declined to 97.82%, down 0.71% YoY.
Analyst sentiment is highly positive, with multiple firms raising price targets and maintaining Buy or Outperform ratings. Price targets range from $160 to $242, reflecting optimism about the Soleno acquisition and long-term growth potential.
